CL2019002325A1 - Combinaciones farmacéuticas para tratar cáncer. - Google Patents

Combinaciones farmacéuticas para tratar cáncer.

Info

Publication number
CL2019002325A1
CL2019002325A1 CL2019002325A CL2019002325A CL2019002325A1 CL 2019002325 A1 CL2019002325 A1 CL 2019002325A1 CL 2019002325 A CL2019002325 A CL 2019002325A CL 2019002325 A CL2019002325 A CL 2019002325A CL 2019002325 A1 CL2019002325 A1 CL 2019002325A1
Authority
CL
Chile
Prior art keywords
pharmaceutical combinations
treat cancer
cys
tyr
ala
Prior art date
Application number
CL2019002325A
Other languages
English (en)
Inventor
Michael Bauer
Leon Hooftman
Barbara Romagnoli
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of CL2019002325A1 publication Critical patent/CL2019002325A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMBINACIONES FARMACÉUTICAS QUE COMPRENDEN UN COMPUESTO DE FÓRMULA I O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO Y CICLO (-TYR-HIS-ALA-CYS-SER-ALA-DPRO-DAB-ARG-TYR-CYS-TYR-GLN-LYS-DPROPRO-) QUE TIENE UN ENLACE DE DISULFURO ENTRE CYS4 Y CYS11 O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO Y SU USO EN UN MÉTODO PARA LA PREVENCIÓN, RETRASO O PROGRESO DE TRATAMIENTO DE CÁNCER EN UN SUJETO.
CL2019002325A 2017-02-20 2019-08-16 Combinaciones farmacéuticas para tratar cáncer. CL2019002325A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17020059 2017-02-20

Publications (1)

Publication Number Publication Date
CL2019002325A1 true CL2019002325A1 (es) 2020-05-15

Family

ID=58108397

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002325A CL2019002325A1 (es) 2017-02-20 2019-08-16 Combinaciones farmacéuticas para tratar cáncer.

Country Status (19)

Country Link
US (2) US20210187059A1 (es)
EP (1) EP3582804A1 (es)
JP (1) JP2020508315A (es)
KR (1) KR20190138633A (es)
CN (1) CN110603051A (es)
AU (1) AU2018221371A1 (es)
BR (1) BR112019017047A2 (es)
CA (1) CA3053857A1 (es)
CL (1) CL2019002325A1 (es)
CO (1) CO2019009000A2 (es)
EA (1) EA201991688A1 (es)
IL (1) IL268416B2 (es)
MA (1) MA47502A (es)
MX (1) MX2019009779A (es)
PE (1) PE20200149A1 (es)
PH (1) PH12019550138A1 (es)
SG (1) SG11201907217RA (es)
UA (1) UA126029C2 (es)
WO (1) WO2018149552A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201908603PA (en) 2017-04-05 2019-10-30 Harvard College Macrocyclic compound and uses thereof
US11548898B2 (en) 2017-07-06 2023-01-10 President And Fellows Of Harvard College Synthesis of halichondrins
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
EP3710454B1 (en) 2017-11-15 2024-01-03 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
WO2022167157A1 (en) * 2021-02-05 2022-08-11 Spexis Ag Eribulin-balixafortide combinations for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6466339B2 (ja) * 2012-12-04 2019-02-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がんの処置におけるエリブリンの使用
MX2016015378A (es) * 2014-05-28 2017-12-04 Eisai R&D Man Co Ltd Uso de eribulina en el tratamiento de cancer.

Also Published As

Publication number Publication date
IL268416B1 (en) 2023-01-01
US20210187059A1 (en) 2021-06-24
CN110603051A (zh) 2019-12-20
PE20200149A1 (es) 2020-01-17
PH12019550138A1 (en) 2020-03-16
CO2019009000A2 (es) 2020-01-17
BR112019017047A2 (pt) 2020-04-28
EA201991688A1 (ru) 2020-02-12
JP2020508315A (ja) 2020-03-19
MA47502A (fr) 2019-12-25
SG11201907217RA (en) 2019-09-27
IL268416A (en) 2019-09-26
EP3582804A1 (en) 2019-12-25
IL268416B2 (en) 2023-05-01
WO2018149552A1 (en) 2018-08-23
UA126029C2 (uk) 2022-08-03
KR20190138633A (ko) 2019-12-13
MX2019009779A (es) 2019-12-19
AU2018221371A1 (en) 2019-08-22
CA3053857A1 (en) 2018-08-23
US20230381270A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
CL2018003290A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
AR101740A1 (es) Terapia de combinación y composiciones
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
DOP2017000111A (es) Inhibidor de cinasa aurora a
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
AR099416A1 (es) Terapia combinada para la hipertensión resistente
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis
EA201990443A1 (ru) Новое применение n,n-бис-2 -меркаптоэтилизофталамида